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Highlights 
Connective tissue growth factor (CTGF, CCN2) is a critical matricellular protein involved in 
key functions in health and when dysregulated, in human disease 
 CCN2 is selectively and exquisitely induced by the TGF- signalling pathway 
 CCN2 appears to mediate many of the activities characteristic of TGF-  
 Inhibition of CCN2 in vitro reduces many of the functional pro-fibrotic activities of 
TGF  
 Deletion of the CCN2 gene in a cell-specific and time-dependent fashion attenuates 
both interstitial fibrosis and pulmonary vascular remodelling in animal models of 




Connective tissue growth factor (CTGF, CCN2) is a matricellular protein which plays key 
roles in normal mammalian development and in tissue homeostasis and repair. In 
pathological conditions, dysregulated CCN2 has been associated with cancer, cardiovascular 
disease, and tissue fibrosis.  In this study, genetic manipulation of the CCN2 gene was 












models of pulmonary fibrosis and pulmonary arterial hypertension (PAH). Knocking down 
CCN2 using siRNA, reduced expression of pro-fibrotic markers (fibronectin p<0.01, collagen 
type I p<0.05, α-SMA p<0.0001, TIMP-1 p<0.05 and IL-6 p<0.05) in TGF- -treated lung 
fibroblasts derived from systemic sclerosis patients. In vivo studies were performed in mice 
using a conditional gene deletion strategy targeting CCN2 in a fibroblast-specific and time-
dependent manner in two models of lung disease. CCN2 deletion significantly reduced 
pulmonary interstitial scarring and fibrosis following bleomycin-instillation, as assessed by 
fibrotic scores (wildtype bleomycin 3.733±0.2667 vs CCN2 knockout (KO) bleomycin 
4.917±0.3436, p<0.05) and micro-CT. In the well-established chronic hypoxia model of 
pulmonary hypertension, CCN2 gene deletion resulted in a significant decrease in pulmonary 
vessel remodelling, less right ventricular hypertrophy and a reduction in the haemodynamic 
measurements characteristic of PAH (RVSP and RV/LV+S were significantly reduced 
(p<0.05) in CCN2 KO compared to WT mice in hypoxic/SU5416 conditions).  These results 
support a prominent role for CCN2 in pulmonary fibrosis and in vessel remodelling 
associated with PAH. Therefore, therapeutics aimed at blocking CCN2 function are likely to 
benefit several forms of severe lung disease.  
 
Abbreviations: Floxed - Flanked by loxP sites 
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Interstitial lung disease (ILD) encompasses a group of disorders involving inflammation and 
fibrosis of lung tissue, which can be idiopathic (IPF), or develop in the context of connective 
tissue diseases such as systemic sclerosis (SSc) (Chambers and Mercer 2015; Denton CP, 
Khanna 2017).  There is significant morbidity and mortality associated with IPF, an ILD with 
a median survival of only 3-5 years post-diagnosis (Gibson et al 2020). Similarly, pulmonary 
involvement, which includes pulmonary hypertension (PH) and pulmonary fibrosis, is the 
leading cause of death in patients with SSc, with extent of ILD being positively associated with 
mortality (Nihtyanova & Denton, 2020). Therefore, despite some advances in treatments 
(Denton & Khanna, 2017; Wongkarnjana et al., 2020), there is still an unmet need to develop 
more effective therapies for fibrotic disease, which requires elucidation of the pathobiology 
and molecular mechanisms underlying pulmonary fibrosis and pulmonary vascular disease.   
Common features amongst the severe pulmonary diseases, and indeed other remodelling 
diseases affecting other target organs including the heart, liver and kidney, is the presence of 
inflammation as a key driver or modifier of disease, promoting pro-fibrotic events leading to 
tissue remodelling, scarring and replacement fibrosis.  Major pathways that have been 
highlighted to be involved in these latter events are the TGF-  and CCN2 pathways. These 
pathways have been studied at the molecular level, and in a variety of disease settings including 
renal fibrosis, lung disease and skin fibrosis (Henrot et al., 2019; Leask, 2017; Miller et al., 
2019; Qi et al., 2008; Wang et al., 2019; Yin & Liu, 2019).  In particular, aberrant expression 
of connective tissue growth factor (CTGF, CCN2) has been extensively explored (Abraham, 












Multiple signalling pathways and cytokines, including  transforming growth factor-β (TGF-β), 
can induce CCN2 expression in various cell types (Takigawa, 2018).  Fibroblasts are a key 
effector cell type in fibrosis and a major source of CCN2, although in adults, CCN2 expression 
is normally tightly regulated and limited to the process of wound healing.  However, in fibrotic 
lesions, CCN2 is often constitutively overexpressed (Abraham, 2008; Leask, 2017). With 
respect to SSc, increased CCN2 expression has been detected in patient groups, notably in 
blister fluids, sera, bronchoalveolar lavage fluids, skin and lung tissues, where CCN2 levels 
have been shown to correlate with clinical parameters, making CCN2 useful as a biomarker 
(Dziadzio et al., 2005; Hasegawa, 2016; Igarashi et al., 1995; Sato et al., 2000; Shi-wen et al., 
2000).  
As a member of the CCN family of matricellular proteins, CCN2 can interact with specific 
receptors (including integrins, heparan sulphate proteoglycans, low-density lipoprotein 
receptor-related proteins and neurotrophic tyrosine kinase receptor type 1 ), ECM proteins 
(including fibronectin and perlecan) and cytokines (including bone morphogenetic proteins, 
TGF-β and vascular endothelial growth factor), in order to modulate cellular functions and 
signalling (Jun & Lau, 2011).  The exact mechanisms underlying the pro-fibrotic actions of 
CCN2 are not yet fully understood, although CCN2 is known to act as a co-factor in enhancing 
the fibrotic activity of TGF-β, and can promote ECM deposition and remodelling (Leask & 
Abraham, 2006).   Previous studies have shown that fibroblast-specific overexpression of 
CCN2 in vivo results in a fibrotic phenotype, characterised by increased collagen deposition in 
the skin, lung and kidney (Doherty et al., 2010; Ponticos et al., 2009; Sonnylal et al., 2010).  
CCN2 also contributes to the expansion of the pool of pro-fibrotic cells by inducing the 
differentiation of tissue-resident fibroblasts, and transdifferentiation of other cell types such as 
epithelial cells and fibrocytes, into activated fibroblasts, or myofibroblasts (Pakshir et al., 2020; 
Sonnylal et al., 2013). This may explain the association of CCN2 expression with expression 
of α-smooth muscle actin (SMA), a marker of myofibroblasts. 
 
A substantial amount of the literature available on pulmonary fibrosis is derived from studies 
in vitro or in animal models.  This reflects the challenges of obtaining human lung tissue for 
research, as the procedure of open lung biopsies is becoming increasingly rare, especially in 
the early stages of disease.  One of the most common in vivo models of pulmonary fibrosis uses 
bleomycin to induce acute lung injury in mice. Bleomycin induces cleavage of DNA strands, 
resulting in pulmonary inflammation and interstitial fibrosis (Walters & Kleeberger, 2008).  In 
this and other animal models of fibrosis, CCN2 and TGF-β work together to produce a fibrotic 
response (Wang et al., 2011).  The fibroblasts present in bleomycin‐induced fibrotic lesions 
express phosphorylated Smad3, indicative of TGF-β signalling (Takagawa et al., 2003), and 
increased CCN2 expression (Howell et al., 2001; Liu et al., 2010), which further supports the 
importance of CCN2 as a pro-fibrotic mediator.  Therefore, impairing the availability or 
activity of CCN2 represents a potential strategy for inhibiting or reversing tissue remodelling 
and fibrosis.  The objective of this study is to investigate the effects of CCN2 gene silencing 
and CCN2 deletion on the development of a disease phenotype using fibroblast cultures and 
two experimentally-induced models of lung disease: bleomycin-induced pulmonary fibrosis 
and the chronic hypoxia/Sugen model of pulmonary arterial hypertension (PAH). In view of 
the critical roles of CCN2 in growth and development, and the observation that conventional 











abnormalities (Ivkovic et al., 2003), we employed conditionally-inducible CCN2-null mice 
(Liu et al. 2011) within these studies.  
 
Materials and Methods 
 
Cell culture 
Human lung fibroblast cultures were established from lung biopsies of patients with diffuse 
cutaneous SSc, and healthy volunteers, as described previously (Abraham et al., 1991). All 
patients fulfilled the American College of Rheumatology / European League against 
Rheumatism criteria for the diagnosis of SSc (van den Hoogen et al., 2013). Informed consent 
and ethical approval were obtained for all procedures (Ethical Approval: Health Research 
Authority, NRES Committee London- Hampstead, Research Ethics Committee (REC) 
reference: 6398). Fibroblasts were cultured in Dulbecco’s Modified Eagle Medium 
supplemented with fetal calf serum (10%), penicillin (100 units/ml) and streptomycin (100 
mg/ml; Life Technologies Inc.) and incubated at 37 °C in a humidified atmosphere of 5% CO2 
in air. All cells were used between passages 2-6 for experiments.  Confluent monolayers were 
made quiescent by incubation in 0.5% bovine serum albumin (BSA)–supplemented DMEM 
for 24 hours before lysis for Western blotting 
CCN2 siRNA knockdown 
Human lung fibroblasts were cultured to 60 – 70% confluence in antibiotic-free complete 
medium. Cells were incubated for 72 hours in the presence of non-targeting control siRNA 
sequences (siNTC; 50 nM; Dharmacon) or a pool of various siRNA sequences targeting 
CCN2 mRNA (siCCN2; 50nM; Dharmacon), in Dharmafect transfection reagent 
(Dharmacon).  CCN2 target sequences used were: ACAAUGACAUCUUUGAAUC, 
AGGAAGAUGUACGGAGACA, CGAUUAGACUGGACAGCUU, 
GAGAGACAUUAACUCAUUA.  Cells were incubated for a further 24 hours with the 
addition of TGF-β (4ng/ml) before being lysed for Western blot analysis.  
Western blot analysis 
Fibroblasts were lysed in radioimmunoprecipitation assay buffer (RIPA) buffer (Sigma) with 
protease inhibitors (Roche). Total protein concentration was determined by BCA assay 
(Pierce).  Samples were heat-denatured under reducing conditions with NuPAGE reducing 
agent (Invitrogen) and subjected to the NuPAGE electrophoresis system (Invitrogen). Proteins 
were transferred onto nitrocellulose membranes (GE Healthcare), which were incubated in 
block buffer (5% non-fat dry milk, 0.1% Tween-20 (Sigma) in phosphate-buffered saline) for 
1 hour, followed by incubation at 4°C overnight with primary antibodies against α-SMA (71 
ng/mL, Dako), collagen type I (0.4 µg/mL , Millipore), CCN2 (0.1 µg/mL, Santa Cruz 
Biotechnology), EDA-fibronectin (2 µg/mL, Sigma-Aldrich), tissue inhibitor of 
metalloproteinase 1 (TIMP-1; ; 0.1  µg/mL, Abcam), and β-tubulin (0.2 µg/mL, Abcam), 
diluted in block buffer (5% non-fat dry milk, 0.1% Tween-20 (Sigma) in phosphate-buffered 
saline). Blots were developed by incubation with horseradish peroxidase (HRP)-conjugated 
secondary antibodies (1:5000, Cell Signalling).  The signal was detected using enhanced 
chemiluminescence (ECL; Pierce) and exposure to Hyperfilm (GE Healthcare). Densitometry 
was performed on the bands using Visionwork LS software, and displayed in arbitrary 












Enzyme-linked immunosorbent assay (ELISA) IL-6 in fibroblast conditioned media 
Conditioned media were aspirated from fibroblast monolayers and centrifuged (350 x g, 5 
minutes) to remove dead cells and debris.  Human IL-6 concentration in the media was 
measured using the DuoSet ELISA Development kit, as recommended by the manufacturer 
(R&D Systems). Values were normalised to total protein concentration for each cell culture, as 
determined by BCA assay. 
Double transgenic CCN2-floxed with Col1 2-CreER inducible CCN2 knockout mice. 
All mice used for experiments were between 6-12 weeks of age at the beginning of the study, 
including males and females.  Animals were genotyped by PCR.  Mice harbouring a floxed 
CCN2 allele have been described previously (Liu et al., 2010). Homozygous CCN2-floxed 
mice were crossed with mice positive for Col1α2-CreER or Col1 2-CreERT2 (Denton et al., 
2003), which express a tamoxifen-inducible Cre recombinase driven by the 2.3-kb mouse 
collagen type I, alpha 2 (Col1α2) promoter. 
CCN2 gene deletion was achieved via cre-recombinase expression, induced by intraperitoneal 
injection with tamoxifen (1 mg/50µL saline; Sigma) (Liu et al., 2011).   
Col1α-R26TmG fibroblast-specific Cre reporter mice  
Generation of a fibroblast-specific Cre-inducible strain was described previously (Li et al., 
2017). Col1α-R26TmG mice harbour the fibroblast-specific enhancer, Col1α-CreERT2 and a 
double fluorescent Cre reporter construct (Muzumdar et al., 2007).  This construct expresses 
membrane-targeted tandem dimer Tomato (tdTomato; red signal) before Cre-mediated 
excision, and enhanced green fluorescent protein (EGFP; green signal) after excision, enabling 
the assessment of cell morphology and tamoxifen-inducible Col1α-CreERT2 activity. 
Bleomycin murine model of pulmonary fibrosis 
The bleomycin-induced murine model was performed by administration of bleomycin (0.12 
units (U) per mouse) or saline via oropharyngeal instillation, as described previously (Ponticos 
et al., 2009).  After 14-21 days (treatment time as indicated in each figure), lung tissue was 
harvested for histology or fixed by inflation for micro-CT imaging.   
Hypoxia/SU5416 murine model of pulmonary arterial hypertension (PAH)  
Mice were treated as previously described (Ciuclan et al., 2011; Derrett-Smith et al., 2013; 
Good et al., 2015).  After 21 days, mice were anesthetized to allow measurement of right 
ventricular systolic pressure (RVSP) and mean arterial aortic pressure using a catheter and 
PowerLab system (AdInstruments), and lung tissue taken for histological analysis as for the 
bleomycin model.   
Micro-computed tomography (micro-CT) imaging of mouse lungs ex vivo 
Lungs were manually inflated prior to removal before being suspended in 3 % potassium Iodide 
(KI) and fixed in 10 % neutral buffered formalin (NBF) overnight at 4°C.  Lungs were then 
dehydrated through a series of graded ethanols: 70 %, 80 %, 90 %, 100 %, 100 %, for 1.5 hours 
in each solution, suspended in hexamethyldisilazane (HMDS) (Sigma Aldrich) for 1.5 hours 
and dried in a fume hood for 2 hours. A Bruker Skyscan 1272 ex vivo micro-CT system was 
used to scan lungs at a resolution of 20 μm, using a 0.25 mm aluminium filter and 0.3° rotation 













Reverse transcription quantitative PCR (RT-qPCR) 
RNA was extracted from whole lungs, after micro-CT scanning. qPCR was performed using 
the SensiMIX™ SYBR® Hi-ROX kit (Bioline) and analysed on a Corbett Rotor Gene RG-
6000 using cycling parameters: initial hold for 10 minutes at 95 °C, 40 cycles of 95 °C for 10 
seconds, 60 °C for 15 seconds, 72 °C for 20 seconds, and acquisition on the green channel. 
Rotor-Gene 6000 series software version 1.7 was used to analyse the results. ΔΔCt values were 
calculated and normalised to the 18S rRNA reference gene. 
Histology and Modified Ashcroft Scale 
Mouse lung tissue was fixed in formalin and embedded in paraffin.  Tissue blocks were 
sectioned (4-6 μm) and mounted on glass slides for haematoxylin and eosin (H&E; Surgipath 
and Sigma) and PicroSirius Red staining (VWR and Raymond Lab) or Goldner trichrome, for 
general morphological analysis and collagen deposition, respectively (Thoua et al., 2012). 
Sections were imaged using the NanoZoomer (Hamamatsu), and analysed using 10X 
magnification in the NDP View software, or imaged using a Zeiss Axio Observer apotome 
microscope and Axio Cam MR R3 camera and viewed in ZEN Blue microscopy software. The 
modified Ashcroft score was used to quantify the extent of fibrosis, as described previously 
(Hubner et al., 2008). Multiple fields were scored following a raster-like pattern until the entire 
section was covered.  The sum of the grades was divided by the number of fields to obtain a 
fibrotic index.  In every field, the predominant degree of fibrosis was recorded as that 
occupying more than half of the field area while areas dominated by bronchial or tracheal tissue 
were omitted. 
Immunohistochemistry and quantitation of DAB staining 
Paraffin-embedded mouse lung tissues were prepared as described above.  Formalin fixed 3 
μm paraffin sections were used for immunostaining. Heat-mediated antigen retrieval was 
performed in citrate buffer (10mM citric acid, pH 6.0).  Endogenous peroxidase was blocked 
using 0.5% hydrogen peroxide. Normal horse serum (2.5%) or normal goat serum (2.5%) was 
used to block tissues for 1 hour, before incubation with anti-CCN2 antibody (4 µg/mL, rabbit 
polyclonal, Abcam) or anti-fibronectin antibody (250ng/mL, mouse IgG, BD Transduction), 
α-SMA (100 ng/mL, Dako, mouse IgG), diluted in antibody diluent (Dako).   Sections were 
the incubated with anti-rabbit ImmPress Polymer reagent (Vector Laboratories) or  goat anti-
mouse HRP (Dako), respectively, before incubating with DAB peroxidase substrate solution 
and counterstained with Meyer’s haematoxylin (Sigma).  Specificity of staining was confirmed 
by incubation sections with an isotype-matched rabbit IgG (Dako) or mouse IgG1 (Santa Cruz) 
control antibody. Sections were imaged using the NanoZoomer (Hamamatsu), and four images 
at 20X magnification were captured for each tissue section in the NDP View software and 
exported as tif-image files.  Staining was semi-quantitatively assessed by measuring the DAB 
stain intensity and normalising against the number of haematoxylin-stained nuclei for each 
image in Fiji (Crowe & Yue, 2019; Schindelin et al., 2012).   
Statistical analysis 
Statistical significance to compare groups was calculated by one-way ANOVA or unpaired 
student two-tailed t-test, as indicated, using Microsoft Excel or GraphPad Prism V8.43.  A 














CCN2 siRNA knockdown attenuated expression of fibrotic protein markers in SSc lung 
fibroblasts 
In order to investigate CCN2 expression in human lung fibroblasts, cell lysates of cultured 
primary fibroblasts derived from lung tissue of HC individuals and SSc patients (n = 3 
biological replicates per group) were analysed by Western blotting and one-way ANOVA with 
Sidak post hoc test.  CCN2 expression was statistically significantly higher in SSc lung 
fibroblasts (1.42 ± 0.561 ADU, p=0.0108; Fig. 1A) than HC fibroblasts (0.606 ± 0.166 ADU).  
Furthermore, to determine the role of CTGF as a fibrotic mediator, siRNA treatment was used 
to examine the effects of knocking down CCN2 on the expression of fibrotic markers in lung 
fibroblasts.  Transfection of HC lung fibroblasts with siCCN2 significantly decreased TGF-β-
induced CCN2 expression (0.508 ± 0.253 ADU, p=0.0019) compared to transfection with 
siNTC (1.89 ± 0.700 ADU).  Expression of CCN2 in HC fibroblasts not treated with TGF-β 
were unchanged with siCTGF treatment as basal levels were low.  In SSc lung fibroblasts, there 
was a trend towards decreased basal CCN2 expression with siCCN2 treatment compared to 
siNTC treatment, although this was not statistically significant (p=0.097).  This may be due to 
the variability in basal CCN2 expression in different SSc cell lines.  Despite this, a decrease in 
basal fibronectin expression was observed with siCCN2 treatment compared to siNTC 
treatment, even in SSc fibroblasts not treated with TGF-β (4.62 ± 3.77 vs 27.9 ± 10.8 ADU, 
p=0.002).  Additionally, knockdown with siCCN2 did significantly lower TGF-β-induced 
CCN2 expression (0.651 ± 0.316 ADU, p<0.0001; Fig. 1A&B). Concomitantly, TGF-β-
induced expression of several profibrotic markers in these SSc fibroblasts, including 
fibronectin (12.8 ± 3.77 vs 37.0 ± 12.2 ADU, p=0.0014), collagen type I (27.4 ± 4.37 vs 51.7 
± 21.6 ADU, p = 0.0469), TIMP-1 (0.314 ± 0.148 vs 1.77 ±1.06 ADU, p=0.0192) and α-SMA 
(1.76 ± 0.230 vs 4.89 ± 0.245 ADU, p<0.0001; Fig. 1C&D), were statistically lower with 
siCCN2-treatment than with siNTC treatment.  Similarly, secreted IL-6 expression was lower 
in siCCN2-treated compared to siNTC-treated HC lung fibroblasts (564 ± 112 vs 810 ± 93 
ng/mL, p=0.0368; Fig 1E). 
 
Fibroblast-specific CCN2 deletion using a tamoxifen-inducible Cre recombinase driven by the 
Col1α2 promoter (Fig 2 and 3) 
Before using the Cre/loxP system for inducible CCN2 KO in mice, activity of the Cre 
recombinase in lung tissue following tamoxifen induction and bleomycin treatment was 
assessed, using the double fluorescent Cre reporter Col1α2-R26TmG mouse.  Inducible 
Col1α2-CreERT2 activity was demonstrated by detection of an EGFP (green) signal in lung 
tissue from tamoxifen-treated mice (Fig. 2A&B).  EGFP expression was detected in cells 
within bronchioles, cells lining alveoli and perivascular cells.  Compared to lungs not treated 
with bleomcyin (Fig. 2A), bleomycin-treated lungs (Fig. 2B) displayed increased regions with 
tdTomato (red) signal, indicating changes to the overall lung architecture. Furthermore, regions 













Subsequently, to induce fibroblast-specific CCN2 deletion in vivo, double transgenic mice 
harbouring the Col1α2-CreERT2 construct and homozygous for CCN2 flox were treated with 
tamoxifen.  There is a marked reduction in CCN2 expression in the structural cells within the 
lung following tamoxifen treatment (Fig. 3A and B). This reduction in CCN2 is mirrored by 
the significant reduction in CCN2 mRNA expression in the lungs of CCN2 mice (n=5) 
compared to untreated control lungs (n=22, unpaired t-test; p<0.001; Fig 3C). 
 
Knockout of CCN2 in Col1 2-CreER mice abrogated bleomycin-induced pulmonary fibrosis 
and remodelling 
To investigate the effect of fibroblast-specific CCN2 deletion on the development of lung 
fibrosis, we examined the extent of bleomycin-induced pulmonary remodeling, in tamoxifen-
induced CCN2 KO mice.  Control mice not treated with tamoxifen were designated as WT for 
CCN2.  CCN2 staining was detected predominantly around blood vessels and bronchioles, and 
in the bleomycin-treated WT mice, predominantly in the expanded alveoli interstitium within 
the fibrotic areas. (Fig. 4A–D).  Semi-quantitative analysis showed that CCN2 staining is 
significantly increased in the WT animals treated with bleomycin (n=4) compared to saline 
(n=7, p<0.0001) and CTGF is significantly reduced in the bleomycin-treated KO mice (n=5) 
compared to bleomycin-treated WT mice (n=4, p<0.05, unpaired t-tests; Fig. 4F).  H&E 
revealed obliteration of alveoli by the presence of florid fibrosis in the lungs of bleomycin-
treated WT mice and not in saline-treated WT mice (Fig. 4G-J).  PicroSirius red staining 
showed that bleomycin-induced collagen deposition was reduced in CCN2 KO mice compared 
to WT mice (Fig. 4K-N).    For semi-quantitative analysis, a fibrotic index was calculated for 
each H&E-stained lung section using the Modified Ashcroft Scale.  A 20% reduction in the 
fibrotic index was observed in bleomycin-treated KO lungs compared to bleomycin-treated 
WT lungs (unpaired t-test, p=0.0277; Fig. 4O). Pulmonary pressures were significantly reduced 
in the bleomycin-treated KO mice compared to bleomycin-treated WT mice (p<0.05; Fig. 4P). 
 
Additionally, micro-CT imaging was performed to assess the extent of pulmonary fibrosis on 
the whole lung tissue prior to sectioning (Fig. 5). Multiple regions of established fibrosis 
were detected in the micro-CT scans of bleomycin-treated lungs (Fig. 5B), which 
corresponded to altered alveolar morphology identified in H&E stained sections (Fig. 5E) and 
increased collagen deposition, as shown by Goldner Trichrome staining (green; Fig. 5H).  
Regions of fibrosis concentrated around bronchioles. Bleomycin-induced fibrosis was 
reduced in CCN2 KO lungs compared to WT lungs (Fig. 5C, F&I).  
 
To investigate the effect of CCN2 deletion on ECM production, we examined the expression 
of COL1α2, COL3 and EDA-fibronectin mRNA, which are precursors of ECM proteins 
associated with fibrotic lung phenotypes (Fig. 6, A-C). Analysis of WT animals identified 
statistically significant upregulation of COL1α2, COL3 and EDA-fibronectin mRNA in 
bleomycin-treated lungs (n=8) compared to untreated (n=15, one-way ANOVA, and Tukey’s 
post hoc test, p˂0.0001). Bleomycin-induced COL1α2 and COL3 mRNA were reduced in 
CCN2 KO lungs (n=8) compared to WT lungs (n=8, p<0.05). Fibronectin expression is 












(p<0.001) and is predominantly located around blood vessels, bronchioles and the alveolar 
interstitium. Localisation of fibronectin in CCN2-deleted animals is similar to that of 
bleomycin-treated WT animals, with perivascular and peribronchial expression (Fig. 6, D-H). 
The changes in the pattern of fibronectin protein expression are similar to those observed by 
RT-qPCR.  
 
Fibroblast-specific CCN2 knockout alters hypoxia/SU5416-induced tissue remodelling and 
increase in pulmonary pressure. 
Since CCN2 KO mice showed reduced arterial pressure, indicated by reduced RVSP, in the 
bleomycin model, we also investigated the impact of CCN2 gene deletion in another lung 
disease model:  a severe model of PAH, which is induced by hypoxia and Sugen/SU5416, an 
inhibitor of vascular endothelial growth factor (VEGF).  After 21 days of hypoxia and SU5416 
treatment, hemodynamic measurements and histological analysis revealed vascular changes 
recapitulating PAH.  We sought to determine whether removal of CCN2 could protect the mice 
from this hypoxia/Su5416-induced PAH phenotype.  In WT mice, hypoxia/SU5416 induced 
elevated RVSP (p<0.001) compared to normoxia/SU5416. In CCN2 KO mice, RVSP was 
significantly reduced (p < 0.05) compared to WT mice, under hypoxic/SU5416 conditions (Fig. 
7A). Hypoxia/SU5416 induced a significant increase (p<0.01) in right ventricular hypertrophy 
(right ventricle:left ventricle plus septum ratio, RV/LV+S). Knocking out CCN2 significantly 
reduced hypoxia/SU5416-induced RV/LV+S (p < 0.05; Fig. 7B). Representative light 
microscopic images of lung sections showed a pathological pulmonary vascular phenotype 
with medial thickening in WT mice exposed to hypoxia/SU5416, and a reduction in vessel 




In the absence of an effective anti-fibrotic treatment for SSc and other fibrotic diseases, the 
aims of this study were to establish whether inhibiting or removing CCN2 gene expression 
could provide an avenue for blocking the development of a fibrotic phenotype in the lung. We 
found that using siRNA to inhibit CCN2 mRNA expression in human SSc lung fibroblasts 
reduced constitutive expression of fibronectin, and TGF-β-induced expression of other fibrotic 
markers. We also found that fibroblast-specific CCN2 knockout mice showed significant 
resistance to bleomycin-induced pulmonary fibrosis and pulmonary hypertension. 
 
SSc is characterised by multi-organ fibrosis with early studies providing evidence of an 
important role for CCN2, particularly in the development of skin fibrosis (Jimenez et al., 2010).  
In this study we focused on the role of CCN2 in lung fibrosis as pulmonary involvement is the 
leading cause of death in SSc (Nihtyanova & Denton, 2020).  Therefore, we examined the 
expression of various fibrotic protein markers in cultured SSc lung fibroblasts, a key effector 
cell type in fibrosis (Garrett et al., 2017). We observed constitutive overexpression of: CCN2; 
fibronectin, a cofactor for TGF-β-induced myofibroblast transdifferentiation; and α-SMA, a 
myofibroblast marker. This is consistent with previous studies reporting dysregulated 












SSc lungs (Hsu et al., 2011; Lindahl G.E. et al., 2013; Renzoni et al., 2004).  This upregulation 
of CCN2 in SSc fibroblasts provided support for CCN2 as a pro-fibrotic mediator and to prove 
this concept, we examined whether knocking down CCN2 expression using siRNA could 
attenuate the fibrotic phenotype in vitro.  We found that knocking down CCN2 reduced 
constitutive fibronectin expression by SSc lung fibroblasts.  Cells were also treated with TGF-
β as it is a potent inducer of CCN2 expression and fibroblast activation.  Downregulation of 
CCN2 following siRNA treatment was most apparent in TGF-β-treated SSc fibroblasts.  
Consequently, significant reductions in fibronectin, collagen type I, α-SMA, TIMP-1 and IL-6 
were observed in TGF-β-treated SSc fibroblasts following treatment with CCN2-targeting 
siRNA. These results may explain previous observations of concomitant upregulation of CCN2 
and other fibrotic proteins such as collagen, α-SMA and IL-6 in SSc tissues (Abraham et al., 
2007; Igarashi et al., 1995; Khan et al., 2012).  These results provides further support that 
CCN2 plays an essential role in the activation of adult lung fibroblasts into α-SMA-expressing 
myofibroblasts, which display a contractile phenotype that contribute to the stiffness of fibrotic 
tissue (Kennedy et al., 2007).   
 
As a matricellular protein, CCN2 may also contribute to tissue stiffness through its interactions 
with multi-ligand receptors, integrins and other ECM components (Lau, 2016).  CCN2 binding 
to integrins can trigger Rho/Rac GTPase signalling pathways, which are involved in regulating 
matrix and vascular stiffness (Chaqour, 2020). Hence CCN2 has been associated with and used 
as a marker in conditions with high tissue stiffness such as various organ fibrosis, 
atherosclerosis and hypertension.  The relative levels of CCN2 and other members of the CCN 
family of matricellular proteins are important in the regulation of tissue remodelling and 
fibrosis (Perbal, 2018).  Indeed expression of CCN2, which is pro-fibrotic, is often inversely 
related to that of CCN3, which is anti-fibrotic; TGF-β treatment of dermal fibroblasts has been 
shown to induce CCN2 expression while downregulating CCN3 expression (Peidl et al., 2019).   
Furthermore, overexpression of CCN3 in fibroblasts blocks the ability of TGF-  to induce 
CCN2, although the molecular mechanism(s) underlying this inhibition is unknown.  
 
Previous work showed that fibroblast-specific overexpression of CCN2 in mice resulted in a 
fibrotic phenotype (Sonnylal et al., 2010). Following on from this, we were interested in 
whether the opposite, fibroblast-specific deletion of CCN2 in mice, could provide protection 
against the development of fibrosis.  Fibroblast-specific CCN2 deletion has been previously 
shown to provide resistance to mouse models of skin fibrosis induced by bleomycin (Leask & 
Abraham, 2006; Liu et al., 2011) or angiotensin-II (Makino et al., 2017).  The data from the 
present study show that fibroblast-specific CCN2 deletion protects against bleomycin-induced 
lung fibrosis and pulmonary hypertension.  CCN2 KO mouse lungs exhibited reduced ECM 
deposition, partial restoration of lung architecture, reduced pulmonary pressure and lower 
levels of COL1α1, COL3, and fibronectin gene expression than WT animals, following 
bleomycin challenge. Furthermore, the deletion of CCN2 from other cell types may be relevant 
for the treatment of other diseases.  For example, myofibroblast-specific CCN2 deletion 
protected mice from development of a muscular dystrophy phenotype by altering collagen 
organisation and improving muscle regeneration (Petrosino et al., 2019).  However, in a mouse 











protective against the cartilage degeneration that associated with OA (Keenan et al., 2020).  
Together these data confirm that CCN2 plays a key role in promoting fibrosis and suggests that 
targeting CCN2 may be a viable option, at least for the treatment of human lung disease. 
 
A potential therapeutic approach in human disease is the use of anti-CCN2 antibodies, the 
benefits of which have been demonstrated in pre-clinical models of fibrosis.  For example, 
mice treated with a neutralizing anti‐CCN2 antibody, pIgY3, after bleomycin lung injury, 
showed reduced activity of the COL1α2 promoter, rescued pathological changes to lung 
architecture and reduced expression of collagen type I and α-SMA (Ponticos et al., 2009).  In 
the study by Makino et al. (2017), the effect of pamrevlumab, (FG-3019), a human monoclonal 
antibody that inhibits the activity of CCN2, was comparable to that of CCN2 gene deletion in 
attenuating skin fibrosis in mice. Similarly, in a rat model of skeletal muscle fibrosis, blockade 
of CCN2 signalling by administration of pamrevlumab reduced the fibrotic phenotype 
including decreased α-SMA and collagen, and restored levels of the anti-fibrotic protein CCN3 
(Barbe et al., 2020).  In IPF, where the current therapies pirfenidone and nintedanib are unable 
to stop disease progression, pamrevlumab is being investigated as a potential therapy and is 
currently in phase 3 clinical trials (Sgalla et al., 2020).  Additionally, anti-CCN2 antibodies 
may be applicable in other diseases such as cancer; pamrevlumab was shown to inhibit pro-
tumour growth cross-talk between carcinoma cells and hepatic stellate cells (Makino et al., 
2018).  This antibody is also in phase 3 trials for the treatment of pancreatic cancer, and in 
phase 2 trials for Duschenne's muscular dystrophy (Leask, 2020).  Therefore, targeting CCN2 
using an anti-CCN2 antibody approach may also be a feasible option for the treatment of lung 
fibrosis in SSc patients. 
 
Conclusions 
The work from this study provides support for blockade of CCN2 expression or activity as a 
feasible therapeutic option for pulmonary fibrosis and pulmonary hypertension such as that in 
SSc and other diseases where CCN2 is overexpressed and plays a key role in pathogenesis.  
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Figure 1.  
CCN2 siRNA attenuates expression of fibrotic protein markers in SSc lung fibroblasts in vitro.  
(A&C) Lung fibroblasts isolated from healthy controls (HC; n=3) and scleroderma (SSc; n=3) patients 
were cultured with recombinant TGF-β (4 ng/ml) to stimulate CCN2 expression, and with CCN2-
specific siRNA (siCCN2) to knockdown CCN2 expression.  Non-target control siRNA (siNTC) was used 
as negative control.  Expression of CCN2 and other fibrotic proteins including fibronectin, collagen 
type I, α-smooth muscle actin (SMA) and tissue inhibitor of metalloproteinase 1 (TIMP1), were 
analysed by Western blotting, and normalised to expression of β-tubulin. (B&D) Densitometry 
analysis of Western blots. (E) Conditioned media collected from TGF-β-treated HC fibroblast cultures 
were analysed by enzyme-linked immunosorbent assay (ELISA), for quantitation of secreted IL-6, 
normalised to total protein in the cell layers, as determined by BCA assay. Bars show mean ± SEM. 
Statistical significance was tested by one-way ANOVA with Sidak multiple comparison, * p < 0.05, ** 
p < 0.01, *** p < 0.001. 
 












Dual fluorescence reporter mice show tamoxifen-inducible Cre recombinase activity in lung tissue 
and changes in lung architecture following bleomycin treatment.  Representative fluorescence 
images of double transgenic adult Col1α2-R26TmG reporter mice containing the mT/mG reporter 
construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene (Li et al., 2017). Tamoxifen was 
administered to all mice on days 1, 3 & 5.  After a 7-day interval, mice were left untreated (A), or 
administered a single oropharyngeal aspiration challenge of bleomycin (0.12 U/mouse; B).  Lungs 
were isolated 14 days after bleomycin treatment. Col1α2-CreERT2 activity is indicated by an EGFP 
signal (green; FITC 519 nm fluorescence channel) while the tdTomato signal (red; mCherry 610 nm 
fluorescence channel) provides an outline of general cell morphology. Tissues were imaged using a 
Zeiss Axio Observer apotome microscope and Axio Cam MR R3 camera. Inserts show enlarged areas 
of image.  Scale bars represent 100 µm. 
 
Figure 3.  
Reduced CCN2 gene expression in lung tissue following tamoxifen-induced fibroblast-specific CCN2 
deletion in adult mice. Lungs were isolated from double transgenic male animals, homozygous for 
CCN2 flox, and positive for Col1α2-CreERT2 14 days after completion of tamoxifen dosing. Lung 
sections from untreated littermate control (A) and tamoxifen-induced (B) mice were stained with 
anti-CCN2 antibody (ab6992; black arrows).  (C) RNA was extracted from whole lungs for 
quantitation of CCN2 mRNA expression by the ∆∆Ct method of RT-qPCR analysis and normalised to 
18S rRNA.  Statistical significance was determined by unpaired t-test (*** p < 0.001). a- alveoli, v- 













Figure 4. Fibroblast-specific CCN2 deletion protects mice from bleomycin-induced histological 
changes and pulmonary arterial hypertension (PAH).  Double transgenic mice, homozygous for CCN2 
flox, and positive for Col1α2-CreER, were administered tamoxifen daily for 5 days to induce CCN2 
deletion (KO, n=5 per group).  Untreated littermate controls were designated as wildtype for CCN2 
(WT, n=7 for saline, n=4 for bleomycin).  After a 7 day interval, mice were treated with saline, or a 
single oropharyngeal instillation of bleomycin (0.12 U/mouse).  After 21 days, right ventricular 
systolic pressure (RVSP) was measured, before lungs were harvested for CCN2 immunostaining  (A–
D), rabbit isotype control staining (E), hematoxylin and eosin (G–J; H&E), and picrosirius red staining  
(K–N). Scale bars represent 50 µm.  (F) Semi-quantitation of CCN2 staining (DAB intensity / nuclei 
count).  (O) Modified Ashcroft scoring of H&E sections to quantify extent of pulmonary fibrosis. (P) 
RVSP was measured for detection of PAH, sample size same as (O). Bars show mean ± S.E.M. 













Figure 5.  
Ex vivo micro computed tomography (micro-CT) analysis shows protection against bleomycin-
induced lung fibrosis in fibroblast-specific CCN2 knockout mice. Tissue analysis of double transgenic 
animals, homozygous for CCN2 flox, and positive for Col1α2-CreERT2 mouse lungs 14 days post-
bleomycin (0.12 U/mouse) treatment. (A-C) Single plane view of micro-CT scan of inflated mouse 
lungs suspended in 3% potassium iodide and fixed in in 10 % neutral buffered formalin. Lungs were 
isolated and manually inflated for scanning, using a SkyScan 1272 micro-CT system at a resolution of 












Nrecon software and visualised using DataViewer. Histological evaluation of lung samples using 
hematoxylin and eosin stain (H&E; D–F) and Goldner’s trichrome stain (G–H). Scale bars represent 
200 µm.  Anatomical features are identified as follows: a- alveoli, Br / br- bronchioles, v- blood 
vessels, He- heart, arrows (red/black) indicate regions of fibrosis. 
 
Figure 6.  
Fibroblast-specific CCN2 deletion reduces bleomycin-induced COL1α2, COL3 and EDA-fibronectin 
expression in mouse lungs. (A – C) RT-qPCR ∆∆Ct analysis of COL1α2, COL3 and EDA fibronectin 
mRNA in double transgenic animals homozygous for CCN2 floxed gene and positive for fibroblast-
specific Col1α2-CreERT2. Mice not treated with tamoxifen were designated as wildtype for CCN2 
(WT, n=15 for saline, n=8 for bleomycin).  Mice administered tamoxifen on days 1, 3 and 5 to induce 
CCN2 deletion were designated CCN2 knockout (KO, n=8). After a 7 day interval a single 
oropharyngeal aspiration challenge of bleomycin (0.12 U/mouse; Bleo) was administered. Lungs 
were isolated 14 days post-bleomycin challenge. ∆∆Ct fold-change are normalised to 18S rRNA as a 
reference gene.  Significance was determined using one-way ANOVA followed by Tukey’s post-hoc 
test.  (D – F) Fibronectin immunohistochemical staining of mouse lung tissue and (G) mouse IgG 
isotype control staining. Scale bars represent 50 µm, a- alveoli, br – bronchioles, v- blood vessels. (H) 
Semi-quantitation of fibronectin DAB staining normalised to haematoxilyn stained nuclei count.  













Figure 7.  
Fibroblast-specific deletion of CCN2 alters hypoxia/SU5416-induced tissue remodelling and increase 
in pulmonary pressure. After 21 days of hypoxia and SU5416 treatment, mice were anesthetized and 
pulmonary pressures measured using a catheter.  (A) Right ventricular systolic pressure (RVSP).  Mice 
not treated with tamoxifen were designated as wildtype for CCN2 (WT).  Mice were treated with 
tamoxifen to induce CCN2 deletion (KO).  Hypoxia/SU5416 induced elevated RVSP compared to 
normoxia/SU5416. In CCN2-null mice (KO), RVSP was significantly reduced (p < 0.05) compared to 
WT mice, under hypoxic/SU5416 conditions. (B) Hypoxia/SU5416 induced a significant increase (p < 
0.01) in right ventricular hypertrophy (right ventricle : left ventricle plus septum ratio, RV/LV+S) in 
WT mice. Knocking out CCN2 significantly reduced hypoxia/SU5416-induced RV/LV+S (p < 0.05). 
Significance was tested by unpaired t-test (* p < 0.05, ** p < 0.01, *** p <0.001; n = 6 per group). (C) 
Representative light microscopic images of α-smooth muscle actin (α-SMA)-stained lung sections 
showing a pathological pulmonary vascular phenotype with medial thickening in mice exposed to 
hypoxia and SU5416.  Scale bars represent 50 µm. Mouse IgG isotype control-stained lung section 
(bottom right). 
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